文献速递呼吸道感染

AS01E佐剂RSV预融合F蛋白疫苗在老年人中三个RSV季节的效力、安全性和免疫原性:AReSVi-006多中心随机观察者盲安慰剂对照3期试验

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2025-04-14

AReSVi-006试验纳入60岁及以上老年人,随机分配接种RSVPreF3 OA或安慰剂,评估三个RSV季节的效力。

要点

  • 效力随时间下降,复种后效力与单剂范围相同。
  • 安全性可接受,严重不良事件发生率低。

核心结论

  • 单剂RSVPreF3 OA在60岁及以上老年人中三个RSV季节内对RSV-LRTD有效,尽管效力随时间下降。

研究设计与样本

  • 多中心、随机、观察者盲、安慰剂对照3期试验,17国275中心,60岁及以上参与者随机1:1接种RSVPreF3 OA或安慰剂。

主要发现

  • 60-69岁、70-79岁、衰弱前及有基础疾病者中均观察到三个季节的效力。
  • 首剂后1年复种效力与单剂范围相同。
  • 严重不良事件相关率<1%,5例死亡被评估为与试验干预相关。

关键数值与推荐

  • 成功标准:RSV-LRTD效力双侧CI下限>20%,RSV亚型LRTD效力双侧CI下限>0%。

临床怎么用

  • 支持RSVPreF3 OA用于60岁及以上老年人预防RSV-LRTD至少三个RSV季节。
  • 复种策略需进一步研究确定。

局限性

  • 效力随时间下降,最佳复种策略未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Duration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed to evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults. METHODS: In this randomised, observer-blind, placebo-controlled, phase 3 trial (AReSVi-006), participants aged 60 years or older in 275 centres (ie, GP practices and clinical research sites) across 17 countries in Africa, Asia, Oceania, Europe, and North America were randomly assigned (1:1) to receive RSVPreF3 OA or placebo before RSV season one. RSVPreF3 OA recipients were re-randomly assigned (1:1) before RSV season two to receive a second RSVPreF3 OA dose (RSV revaccination group) or placebo (RSV single-dose group). Recipients of placebo before RSV season one also received placebo before season two (placebo group). The primary objective (efficacy against first occurrence of RSV-LRTD over one RSV season) was reported previously. Confirmatory secondary objectives were to demonstrate efficacy over three RSV seasons of a single RSVPreF3 OA dose and of a first dose followed by revaccination 1 year later, against RSV-LRTD, overall and by RSV subtype (success criteria: lower limits of two-sided CIs around efficacy estimates >20% [RSV-LRTD] and >0% [RSV-LRTD by RSV subtype]). This study is registered with ClinicalTrials.gov, NCT04886596, and is complete. FINDINGS: Participants were enrolled between May 25, 2021, and Jan 31, 2022. Efficacy analyses included 12 468 RSVPreF3 OA recipients and 12 498 placebo recipients. Cumulative efficacy over three seasons of one RSVPreF3 OA dose was 62·9% (97·5% CI 46·7-74·8) against RSV-LRTD, 69·8% (42·2-85·7) against RSV A-related LRTD, and 58·6% (35·9-74·1) against RSV B-related LRTD (median follow-up from day 15 post-dose one 30·6 months [IQR 26·2-32·0]). Efficacy was observed over three seasons among participants aged 60-69 years, participants aged 70-79 years, pre-frail participants (ie, those with a walking speed of 0·4-0·99 m/s in a gait speed test), and participants with pre-existing conditions that increase the RSV-LRTD risk. Efficacy against RSV-LRTD decreased over time. A first RSVPreF3 OA dose followed by revaccination 1 year later had an efficacy that was within the same range as that of one dose. RSVPreF3 OA showed a clinically acceptable safety profile. Between dose one and trial end, eight (<1%) participants in the RSV single-dose group, 12 (<1%) in the RSV revaccination group, and 12 (<1%) in the placebo group had a serious adverse event considered to be related to the trial intervention by the investigator. Five deaths were assessed as related to the trial intervention by the investigator: three in the vaccine groups (cardiopulmonary failure, cardiac arrest, and left ventricular failure) and two in the placebo group (death of unknown cause and pulmonary embolism). INTERPRETATION: A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons in people aged 60 years or older, despite a decrease in efficacy over time. Further research is needed to establish the optimal revaccination strategy. These results support the favourable benefit-risk profile of RSVPreF3 OA to help protect against RSV-LRTD for at least three RSV seasons. FUNDING: GSK.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Ison MG, Papi A, Athan E, et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025. PMID: 40245915. doi:10.1016/S2213-2600(25)00048-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。